Scott+Scott Attorneys at Law LLP ("Scott+Scott"), a national shareholder and consumer rights litigation firm, reminds investors that a class action lawsuit has been filed against Cocrystal Pharma, Inc. ("Cocrystal" or the "Company"), formerly known as BioZone Pharmaceuticals, Inc. ("BioZone") COCP and other defendants, related to alleged violations of federal securities laws. If you purchased Cocrystal or BioZone securities between September 23, 2013 and September 7, 2018, you are encouraged to contact a Scott+Scott attorney at (844) 818-6982 for more information. The lead plaintiff deadline is November 19, 2018.
Cocrystal is a clinical stage biotechnology company that develops antiviral therapeutics that target the replication machinery of hepatitis viruses, influenza viruses, and noroviruses.
The lawsuit alleges that defendants made false and/or misleading statements and/or failed to disclose that: (1) defendants were engaged in a pump-and-dump scheme to artificially inflate Cocrystal's stock price; (2) this illicit scheme would result in governmental scrutiny, including from the SEC; (3) defendants failed to abide by SEC disclosure regulations; and (4) as a result, defendants' statements about Cocrystal's business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
On September 7, 2018, the SEC issued a press release entitled "SEC Charges Microcap Fraudsters for Roles in Lucrative Market Manipulation Schemes," which included Phillip Frost, a Director of Cocrystal, as a defendant.
What You Can Do
If you purchased Cocrystal or BioZone securities between September 23, 2013 and September 7, 2018, inclusive, or if you have questions about this notice, please contact attorney Joe Pettigrew at (844) 818-6982, or at jpettigrew@scott-scott.com.
About Scott+Scott Attorneys at Law LLP
Scott+Scott has significant experience in prosecuting major securities, antitrust, and employee retirement plan actions throughout the United States. The firm represents pension funds, foundations, individuals, and other entities worldwide with offices in New York, London, Connecticut, California, and Ohio.
Attorney Advertising
View source version on businesswire.com: https://www.businesswire.com/news/home/20181113005823/en/
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.